Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.
16d
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Zacks Investment Research on MSN
Why Recursion Pharmaceuticals (RXRX) outpaced the stock market today
Recursion Pharmaceuticals (RXRX) ended the recent trading session at $3.34, demonstrating a +1.21% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.38%.
Zacks Investment Research on MSN
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving -3.13% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.28%. On ...
Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Invest In According to Billionaires.
Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...
Which Is a Better Investment, Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. Stock?
Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results